[A19-79] Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37

Last updated 17.10.2019

Project no.:
A19-79

Commission:
Commission awarded on 09.09.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Topic:
Digestion, metabolism and hormones

Indication:

Adults with type 1 diabetes and body mass index ≥ 27 kg/m2, when insuline alone provides no adequate glycaemic control despite optimum insulin therapy

Result of dossier assessment:

Due to data subsequently submitted now indication of minor added benefit for patients in whom the inadequate glycaemic control is not associated with severe hypoglycaemia

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2019-10-17 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form